Welcome to our dedicated page for KAZIA THERAPEUTICS SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KAZIA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KAZIA THERAPEUTICS's regulatory disclosures and financial reporting.
Kazia Therapeutics Limited files a prospectus supplement registering 266,666 American Depositary Shares (ADSs) as set forth on the prospectus supplement dated June 2, 2026. The supplement incorporates a Form 6-K reporting the appointment of James Levine as Chief Financial Officer, effective June 1, 2026, and summarizes his employment terms.
The prospectus supplement discloses that the ADSs trade on Nasdaq under the symbol KZIA and notes a last reported sale price of $12.56 per ADS on June 1, 2026. The Form 6-K describes Mr. Levine’s compensation package, including a $475,000 base salary, a 40% target bonus (prorated for 2026), and a proposed grant of 200,000 ADS options subject to Board approval and vesting conditions.
Kazia Therapeutics Limited files a prospectus supplement registering 95,110 American Depositary Shares (ADSs) representing 47,555,000 Ordinary Shares as described on the supplement cover. The supplement incorporates a Form 6-K dated June 2, 2026 and updates the Prospectus dated December 22, 2025.
The Form 6-K included in the supplement furnishes a press release announcing the appointment of James Levine as Chief Financial Officer effective June 1, 2026, and summarizes his employment terms: a $475,000 base salary, a 40% target bonus (prorated for 2026), and a proposed grant of 200,000 ADS options subject to Board approval and vesting terms. The ADSs trade on Nasdaq under the symbol KZIA.
Kazia Therapeutics Limited has appointed James Levine as Chief Financial Officer, effective June 1, 2026. Under his employment agreement, he will receive an annual base salary of US$475,000, an annual target bonus equal to 40% of base salary (prorated for 2026), and options over 200,000 American Depositary Shares.
One-third of the options vest at the start of employment, with the rest vesting in equal yearly installments, and all options are forfeited if he leaves voluntarily within the first year. If his role ends without cause or he resigns for good reason, he may receive up to 12 months’ salary and health coverage in certain change-in-control situations, or up to 6 months’ salary and health coverage otherwise, subject to conditions including a release of claims.
Kazia Therapeutics Ltd reports beneficial ownership of 2,114,649 American Depositary Shares, representing 18.5% of the class as of May 26, 2026. The filing calculates the class base on 11,426,899 ADS outstanding as of March 12, 2026, per the issuer's Form F-3. The schedule lists the reporting person as Jorey Chernett with sole voting and dispositive power over the disclosed ADS.
Kazia Therapeutics is supplementing its registration materials to cover 232,956 American Depositary Shares, representing 116,478,000 Ordinary Shares. The supplement incorporates a May 26, 2026 Form 6-K announcing expansion of a Phase 1b paxalisib trial in advanced triple negative breast cancer: planned enrollment will increase from 12 to 36 patients to further assess safety, dose optimization and preliminary efficacy. The press release notes continued encouraging safety and tolerability and anticipates additional updates through 2026 into 2027.
Kazia Therapeutics Limited filed a prospectus supplement registering 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares and furnished a Form 6-K attaching a May 26, 2026 press release. The release announces an expansion of its Phase 1b paxalisib trial in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients based on continued encouraging safety and tolerability data. The supplement updates the Prospectus dated December 22, 2025 and attaches the press release; the ADSs trade on Nasdaq under the symbol KZIA.
Kazia Therapeutics filed a prospectus supplement dated May 26, 2026 registering 10,700,211 American Depositary Shares representing 5,350,105,500 ordinary shares as part of its Form F-1 registration. The supplement incorporates a Form 6-K announcing an expansion of its ongoing Phase 1b trial of paxalisib in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients to further evaluate safety, dose optimization and preliminary efficacy. The ADSs trade on Nasdaq under the symbol KZIA, with a reported last sale price of $13.66 per ADS on May 22, 2026. Additional clinical updates are expected through 2026 and into 2027.
Kazia Therapeutics Limited files a prospectus supplement registering 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares as part of its existing registration. The supplement attaches a Form 6-K disclosing an expansion of the ongoing Phase 1b paxalisib trial in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients. The ADSs trade on Nasdaq under the symbol KZIA; the last reported sale price was $13.66 per ADS on May 22, 2026.
Kazia Therapeutics is expanding its ongoing Phase 1b trial of lead drug paxalisib in advanced triple negative breast cancer. Planned enrollment will rise from 12 to 36 patients after continued encouraging safety, tolerability and early clinical activity in combination with pembrolizumab and chemotherapy.
The larger study is intended to refine dosing and better assess early measures of benefit such as objective response rate, progression-free survival and translational biomarkers. Kazia highlights preclinical data supporting dual PI3K/mTOR inhibition in TNBC and notes that additional clinical updates are anticipated throughout 2026 and into 2027.
Kazia Therapeutics Ltd filed an initial Form 3 for Sudha Rao